Table 2.
Key findings related to the role of selenium in human clinical trials.
| Study | Year | Patients | Selenium | Dose | Levels of Se/GPX | Mortality |
|---|---|---|---|---|---|---|
| Angstwurm [123] | 1999 | 42 | Selenite | 535 μg/24hr/3d to 285 μg/24hr/3d to 155 μg/24hr/3d then maintained as control group on 35 μg/24hr/d | Increased | Total p=0.13 Post hoc p=0.0278 |
| Berger [124] | 2006 | 41 | Selenite | copper 2.5-3.1 mg/d selenium 315-380μg/d zinc 26.2 - 31.4 mg/d | Increased | p=0.57 |
| Angstwurm [125] | 2007 | 249 (238, 189) | Selenite | 1,000 μg/bolus followed by 1,000 μg/24hr/14d or placebo | Increased | p=.109 p=0.049 |
| Forceville [126] | 2007 | 60 | Selenite | 4,000 μg/24hr/1d to 1000 μg/24hr/9d or placebo | N/A* | p=0.691 |
| Mishra [127] | 2007 | 40 | Selenite | 474 μg/24hr/3d to 316 μg/24hr/3d to 158 μg/24hr/3d then maintained as control group on 31.6 μg/24hr/d | Increased | p=0.94 |
| Andrews [128] | 2011 | 502 | Selenite | Parenteral glutamine 20.2 g/24hr/7d or selenium 500 μg/24hr/7d | N/A* | p=0.54 |
| Manzanares [129] | 2011 | 35 | Selenite | 1,000 μg/bolus followed by 1,000 μg/24hr/14d or placebo | Increased | p=0.55 p=0.95 |
| Valenta [130] | 2011 | 150 | Selenite | 1000μg/24hr/1d to 500μg/24hr/13d then maintained as controls group on 75μg/24hr/14d | Increased | p=0.367 |
| Janka [131] | 2013 | 72 | Selenite | 750 μg/24 h/6d or placebo | Increased | p=0.159 |
*
N/A signifies information that is not available.